tiprankstipranks
Trending News
More News >
Genscript Biotech (HK:1548)
:1548
Hong Kong Market

Genscript Biotech (1548) Stock Forecast & Price Target

Compare
7 Followers
See the Price Targets and Ratings of:

1548 Analyst Ratings

Hold
1Ratings
Hold
0 Buy
1 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Genscript
Biotech
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1548 Stock 12 Month Forecast

Average Price Target

HK$16.01
▲(4.26%Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Genscript Biotech in the last 3 months. The average price target is HK$16.01 with a high forecast of HK$16.00 and a low forecast of HK$16.00. The average price target represents a 4.26% change from the last price of HK$15.36.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"HK$9","14":"HK$14","19":"HK$19","11.5":"HK$11.5","16.5":"HK$16.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16.0000000048824,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.013941554,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$16.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.0000000048824,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,11.5,14,16.5,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2021","6":"Jan<br/>2022","9":"May<br/>2024","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.46,12.732307692683262,13.004615385366524,13.276923078049785,13.549230770733047,13.821538463416308,14.09384615609957,14.36615384878283,14.638461541466093,14.910769234149353,15.183076926832616,15.455384619515875,15.727692312199137,{"y":16.0000000048824,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.46,12.733380119538463,13.006760239076923,13.280140358615386,13.553520478153846,13.826900597692308,14.100280717230769,14.373660836769231,14.647040956307691,14.920421075846154,15.193801195384614,15.467181314923076,15.740561434461537,{"y":16.013941554,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.46,12.732307692683262,13.004615385366524,13.276923078049785,13.549230770733047,13.821538463416308,14.09384615609957,14.36615384878283,14.638461541466093,14.910769234149353,15.183076926832616,15.455384619515875,15.727692312199137,{"y":16.0000000048824,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.1,"date":1627776000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.1,"date":1630454400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.1,"date":1633046400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.1,"date":1635724800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.1,"date":1638316800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.1,"date":1640995200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.1,"date":1640995200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.1,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.5,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.64,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.92,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$16.00Average Price TargetHK$16.01Lowest Price TargetHK$16.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on HK:1548
TipRanks AITipRanks
Not Ranked
TipRanks
HK$16
Hold
4.17%
Upside
Reiterated
06/19/25
The stock's strong technical indicators and revenue growth are offset by significant profitability challenges and valuation concerns. Positive momentum and a robust balance sheet provide some upside potential, but the company needs to address its financial inefficiencies for sustained growth.
AI Firm
HK$18HK$16
Hold
4.17%
Upside
Reiterated
06/19/25
Morgan Stanley Analyst forecast on HK:1548
Unknown AnalystMorgan Stanley
Not Ranked
Morgan Stanley
HK$18.6HK$21.9
Buy
42.58%
Upside
Reiterated
03/14/25
We lift our PT for GenScript and maintain our OW rating on the company due to three things: 1) GenScript's leading-edge technology platform and industry position in protein and the gene synthesis area with limited qualified competitors; 2) recovery order trend in the CRO and CDMO segments with eased geopolitical overhangs, and 3) outperforming enzyme business thanks to growing wallet share from key account clients as well as accelerated ex-China market expansion.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on HK:1548
TipRanks AITipRanks
Not Ranked
TipRanks
HK$16
Hold
4.17%
Upside
Reiterated
06/19/25
The stock's strong technical indicators and revenue growth are offset by significant profitability challenges and valuation concerns. Positive momentum and a robust balance sheet provide some upside potential, but the company needs to address its financial inefficiencies for sustained growth.
AI Firm
HK$18HK$16
Hold
4.17%
Upside
Reiterated
06/19/25
Morgan Stanley Analyst forecast on HK:1548
Unknown AnalystMorgan Stanley
Not Ranked
Morgan Stanley
HK$18.6HK$21.9
Buy
42.58%
Upside
Reiterated
03/14/25
We lift our PT for GenScript and maintain our OW rating on the company due to three things: 1) GenScript's leading-edge technology platform and industry position in protein and the gene synthesis area with limited qualified competitors; 2) recovery order trend in the CRO and CDMO segments with eased geopolitical overhangs, and 3) outperforming enzyme business thanks to growing wallet share from key account clients as well as accelerated ex-China market expansion.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Genscript Biotech

1 Month
xxx
Success Rate
0/0 ratings generated profit
Average Return
0.00%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in - of your transactions generating a profit, with an average return of 0.00% per trade.
3 Months
xxx
Success Rate
0/0 ratings generated profit
Average Return
0.00%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in - of your transactions generating a profit, with an average return of 0.00% per trade.
1 Year
Unknown AnalystMorgan Stanley
Not Ranked
Success Rate
0/0 ratings generated profit
Average Return
0.00%
reiterated a buy rating 4 months ago
Copying Unknown Analyst's trades and holding each position for 1 Year would result in - of your transactions generating a profit, with an average return of 0.00% per trade.
2 Years
xxx
Success Rate
0/0 ratings generated profit
Average Return
0.00%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in - of your transactions generating a profit, with an average return of 0.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1548 Analyst Recommendation Trends

Rating
Mar 24
May 24
Mar 25
May 25
Jun 25
Strong Buy
2
3
3
2
1
Buy
0
0
0
0
0
Hold
1
0
0
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
3
3
3
3
In the current month, 1548 has received 1 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 1548 average Analyst price target in the past 3 months is 16.01.
Each month's total comprises the sum of three months' worth of ratings.

1548 Financial Forecast

1548 Earnings Forecast

Next quarter’s earnings estimate for 1548 is HK$0.62 with a range of HK$0.62 to HK$0.62. The previous quarter’s EPS was HK$11.47. 1548 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.65% of the time in the same period. In the last calendar year 1548 has Outperformed its overall industry.
Next quarter’s earnings estimate for 1548 is HK$0.62 with a range of HK$0.62 to HK$0.62. The previous quarter’s EPS was HK$11.47. 1548 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.65% of the time in the same period. In the last calendar year 1548 has Outperformed its overall industry.

1548 Sales Forecast

Next quarter’s sales forecast for 1548 is HK$4.34B with a range of HK$4.34B to HK$4.34B. The previous quarter’s sales results were ―. 1548 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 51.30% of the time in the same period. In the last calendar year 1548 has Outperformed its overall industry.
Next quarter’s sales forecast for 1548 is HK$4.34B with a range of HK$4.34B to HK$4.34B. The previous quarter’s sales results were ―. 1548 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 51.30% of the time in the same period. In the last calendar year 1548 has Outperformed its overall industry.

1548 Stock Forecast FAQ

What is HK:1548’s average 12-month price target, according to analysts?
Based on analyst ratings, Genscript Biotech’s 12-month average price target is 16.01.
    What is HK:1548’s upside potential, based on the analysts’ average price target?
    Genscript Biotech has 4.26% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Genscript Biotech a Buy, Sell or Hold?
          Genscript Biotech has a consensus rating of Hold, which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Genscript Biotech’s share price target?
            The average share price target for Genscript Biotech is 16.01. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$16.00 ,and the lowest forecast is HK$16.00. The average share price target represents 4.26% Increase from the current price of HK$15.36.
              What do analysts say about Genscript Biotech?
              Genscript Biotech’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of Genscript Biotech?
                To buy shares of HK:1548, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis